secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2023-04-26T23:59:59+00:00
Accession:  0001564590-23-006238
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q1 revenue $287.6M; proprietary products up 25% YoY; GAAP EPS -$0.25, non-GAAP EPS $0.01
--------------------------------------------------------------------------------

- Proprietary product net sales $214.7M (+25% YoY); LYBALVI grew 173% to $38.0M.
- GAAP net loss $41.8M ($0.25 loss/share) vs $35.9M loss prior year.
- Non-GAAP net income $2.4M ($0.01 EPS) vs $19.6M ($0.12) prior year.
- Oncology separation on track for H2 2023; new company to be Mural Oncology.
- Favorable second interim award in Janssen arbitration; ~$194M back royalties due.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000156459023006238/0001564590-23-006238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000156459023006238/alks-8k_20230426.htm
  HTML page:      https://secwatch.observer/filing/0001564590-23-006238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer